[ad_1]
On Tuesday, the US Food and Drug Administration published a brief opinion in which it spoke positively about Moderna’s vaccine against Covid-19, and the agency’s statement was characterized by an optimistic tone.
She said that "There are no specific security concerns that prevent a quick license to use"And it confirmed the overall effectiveness of the vaccine at a rate of 94.1%.
But the panel of consultants, which includes infectious disease, epidemiology and immunology experts from across the country, looked at other issues, including the possibility of severe allergic reactions.
Alaska state officials revealed Wednesday that a healthcare worker suffered a severe allergic reaction after receiving the Pfizer vaccine on Tuesday, knowing she had no history of allergies, but her health improved after being treated with allergy medications.
“>
After their discussions, which lasted hours, the committee confirmed the safety and efficacy of the vaccine and the members voted 20 to zero.
The vaccine is expected to obtain approval from the US Authority for emergency use within hours, being the second authorized for use, after the Pfizer-Bionic vaccine, which was approved last Friday.
On Tuesday, the US Food and Drug Administration published a brief opinion in which it spoke positively about Moderna’s vaccine against Covid-19, and the agency’s statement was characterized by an optimistic tone.
He said “there are no specific safety concerns preventing the urgent issuance of a use license” and confirmed the overall effectiveness of the vaccine at 94.1 percent.
But the panel of consultants, which includes infectious disease, epidemiology and immunology experts from across the country, looked at other issues, including the possibility of severe allergic reactions.
Alaska state officials revealed Wednesday that a healthcare worker suffered a severe allergic reaction after receiving the Pfizer vaccine on Tuesday, knowing she had no history of allergies, but her health improved after being treated with allergy medications.
[ad_2]
